{"organizations": [], "uuid": "d93a98e8241a18d3207ddf5ec080b06fd8069ec8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-rigel-makes-statement-regarding-we/brief-rigel-makes-statement-regarding-website-error-idUSFWN1RP124", "country": "US", "domain_rank": 408, "title": "BRIEF-Rigel Makes Statement Regarding Website Error", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T23:03:00.000+03:00", "replies_count": 0, "uuid": "d93a98e8241a18d3207ddf5ec080b06fd8069ec8"}, "author": "", "url": "https://www.reuters.com/article/brief-rigel-makes-statement-regarding-we/brief-rigel-makes-statement-regarding-website-error-idUSFWN1RP124", "ord_in_thread": 0, "title": "BRIEF-Rigel Makes Statement Regarding Website Error", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "rigel pharmaceuticals inc", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 8:04 PM / Updated 6 minutes ago BRIEF-Rigel Makes Statement Regarding Website Error Reuters Staff \nApril 12 (Reuters) - Rigel Pharmaceuticals Inc: * RIGEL MAKES STATEMENT REGARDING WEBSITE ERROR \n* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17 \n* DUE TO AN ERROR, INACCURATE INFORMATION WAS DISPLAYED REGARDING U.S. FDA’S REVIEW OF NDA FOR FOSTAMATINIB \n* CO’S WEBSITE HAS BEEN CORRECTED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-12T23:03:00.000+03:00", "crawled": "2018-04-12T23:13:11.003+03:00", "highlightTitle": ""}